Berna Biotech AG
|
| Company Information |
| Address |
Rehhagstrasse 79
3018 Bern |
| Country |
Switzerland |
| Phone |
+41 (0) 31 980 61 11 |
| Internet |
www.berne-biotech.ch |
| Business Sector |
Biotechnology |
| Brief Overview |
Berna Biotech AG is a biotechnology company specialised in the development and production of immunobiological preparations, mainly viral and bacterial vaccines. The firm was founded in 1898 under the name of Schweiz. Serum- und Impfinstitut Bern. |
| |
| People |
| Chief Executive Officer |
Kuno Sommer |
| Chief Financial Officer |
Rolf Gasser |
| Chairman of the Board |
Peter Giger |
| Auditors |
KPMG Fides Peat |
| No. of Employees |
698 |
| |
| Going Public |
| Exchange |
Swiss Exchange |
| IPO Date |
June 26, 2001 |
| Share Identification Number |
1246277 |
| Symbol |
BBIN |
| Subscription Period |
06,26,2001 to 07,06,2001
|
| Lead Underwriter |
Lombard Odier & Cie. |
| Underwriters |
Berner Kantonalbank |
| Total No. of Shares in Issue after Going Public |
1,000,000 |
| No. of Offered Shares |
1,000,000 |
| Total No. of Issued Share
|
100% |
| Firm Offer Price |
CHF 912 |
| Expected Market Cap. |
CHF 912
Mio. |
| First Day Close |
CHF 880 |
| |
|
|
| Last Fiscal Year End Date Prior to Going Public |
December 31, 2000 |
|
Change Compared to Prior Year
|
| Turnover 2000 |
|
| Turnover 1999 |
|
|
Change Compared to Prior Year |
| Operating Profit, EBIT 2000 |
|
| Operating Profit, EBIT 1999 |
|
|
Change Compared to Prior Year |
| Profit Before Tax 2000 |
|
| Profit Before Tax 1999 |
|
|
Change Compared to Prior Year |
| Company Profit 2000 |
|
| Company Profit1999 |
|
| |
|
| Company Profit
2000 reflects |
-12.7 % of Turnover |
| Company Profit
1999 reflects |
4 % of Turnover
|
| |
|
| Equity on Last Balance Date |
176,975 |
| Total Assets |
264,248 |
| Ratio of Equity to Total Capital on Balance Date |
67 % |
| Last Return on Equity (ROE) |
-12.9 % |
| |
| Notes |
Prior to going public, shares of the company were traded outside an institutional stock exchange.
Capital inrease of 200'000 shares at a price of CHF 760.-. Holders of four shares prior to the capital increase posess a right to purchase one new share. The related rights are traded from June 26 until July 6. Dead line for subsription for new shares ends July 9.
Extraordinary costs of CHF 27.5 Mio for reorganisation during the last fiscal period. |